CN103127136A - Skin drug composition containing methylprednisolone aceponate and amino acid - Google Patents
Skin drug composition containing methylprednisolone aceponate and amino acid Download PDFInfo
- Publication number
- CN103127136A CN103127136A CN2011103919264A CN201110391926A CN103127136A CN 103127136 A CN103127136 A CN 103127136A CN 2011103919264 A CN2011103919264 A CN 2011103919264A CN 201110391926 A CN201110391926 A CN 201110391926A CN 103127136 A CN103127136 A CN 103127136A
- Authority
- CN
- China
- Prior art keywords
- methylprednisolone aceponate
- dermatologic compositions
- compositions
- dermatologic
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DALKLAYLIPSCQL-YPYQNWSCSA-N methylprednisolone aceponate Chemical compound C1([C@@H](C)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CC)[C@@]2(C)C[C@@H]1O DALKLAYLIPSCQL-YPYQNWSCSA-N 0.000 title claims abstract description 64
- 229960002037 methylprednisolone aceponate Drugs 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 239000003814 drug Substances 0.000 title abstract description 13
- 229940079593 drug Drugs 0.000 title abstract description 10
- 150000001413 amino acids Chemical class 0.000 title abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000003112 inhibitor Substances 0.000 claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 238000010521 absorption reaction Methods 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 239000003623 enhancer Substances 0.000 claims description 12
- -1 hydroxypropyl Chemical group 0.000 claims description 12
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 claims description 10
- 229940068171 ethyl hexyl salicylate Drugs 0.000 claims description 10
- FCGXLCNBWYIEAA-UHFFFAOYSA-N 1,3-benzothiazol-6-ylmethanamine Chemical compound NCC1=CC=C2N=CSC2=C1 FCGXLCNBWYIEAA-UHFFFAOYSA-N 0.000 claims description 7
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- 239000000080 wetting agent Substances 0.000 claims description 6
- 230000003204 osmotic effect Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 238000000518 rheometry Methods 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000004034 viscosity adjusting agent Substances 0.000 claims description 4
- 230000002421 anti-septic effect Effects 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 239000003002 pH adjusting agent Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 239000000306 component Substances 0.000 claims description 2
- 239000006184 cosolvent Substances 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 abstract description 9
- 108010021487 Nitric Oxide Synthase Proteins 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000003862 amino acid derivatives Chemical class 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 72
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 29
- 238000000034 method Methods 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 19
- 239000008215 water for injection Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 238000003756 stirring Methods 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- 239000003862 glucocorticoid Substances 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 238000012546 transfer Methods 0.000 description 11
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 208000010668 atopic eczema Diseases 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 241000233866 Fungi Species 0.000 description 8
- 201000008937 atopic dermatitis Diseases 0.000 description 8
- 239000012467 final product Substances 0.000 description 8
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 229960000502 poloxamer Drugs 0.000 description 7
- 229920001983 poloxamer Polymers 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 235000011121 sodium hydroxide Nutrition 0.000 description 7
- 229960004224 tyloxapol Drugs 0.000 description 7
- 229920001664 tyloxapol Polymers 0.000 description 7
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 7
- 201000004624 Dermatitis Diseases 0.000 description 6
- 206010012434 Dermatitis allergic Diseases 0.000 description 6
- 206010017533 Fungal infection Diseases 0.000 description 6
- 208000031888 Mycoses Diseases 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- 230000035699 permeability Effects 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 229940082484 carbomer-934 Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229940075507 glyceryl monostearate Drugs 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 229940057995 liquid paraffin Drugs 0.000 description 5
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 5
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- ONYFNWIHJBLQKE-ZETCQYMHSA-N N(6)-acetimidoyl-L-lysine Chemical compound CC(=N)NCCCC[C@H](N)C(O)=O ONYFNWIHJBLQKE-ZETCQYMHSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003871 white petrolatum Substances 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical group CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- OSOIQJGOYGSIMF-UHFFFAOYSA-N cyclopentadecanone Chemical compound O=C1CCCCCCCCCCCCCC1 OSOIQJGOYGSIMF-UHFFFAOYSA-N 0.000 description 2
- 230000035617 depilation Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000011167 hydrochloric acid Nutrition 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 229960003639 laurocapram Drugs 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- SDDKIZNHOCEXTF-UHFFFAOYSA-N methyl carbamimidothioate Chemical compound CSC(N)=N SDDKIZNHOCEXTF-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229960003753 nitric oxide Drugs 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 235000011118 potassium hydroxide Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
- OUCGJMIVSYHBEC-UHFFFAOYSA-N 2-ethylhexyl 2-ethylhexanoate Chemical compound CCCCC(CC)COC(=O)C(CC)CCCC OUCGJMIVSYHBEC-UHFFFAOYSA-N 0.000 description 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000227633 Ocotea pretiosa Species 0.000 description 1
- 235000004263 Ocotea pretiosa Nutrition 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004137 mechanical activation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000000236 nitric oxide synthase inhibitor Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- INGMGRULDUBWPK-UHFFFAOYSA-N octyl 4-amino-2,3-dimethylbenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=C(N)C(C)=C1C INGMGRULDUBWPK-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000059 polyethylene glycol stearate Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- CSYSULGPHGCBQD-UHFFFAOYSA-N s-ethylisothiouronium diethylphosphate Chemical compound CCSC(N)=N.CCOP(O)(=O)OCC CSYSULGPHGCBQD-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A skin drug composition containing methylprednisolone aceponate and an amino acid comprises the methylprednisolone aceponate which serves as an active ingredient, an amino acid derivative which serves as a nitric oxide synthase (NOS) inhibitor, one or more types of drug auxiliary materials applicable to skin, and the balance water.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, a kind of 17-hydroxy-11-dehydrocorticosterone and amino acid whose dermatologic compositions of containing.
Background technology
Glucocorticoid has antiinflammatory, antiallergic, rheumatism, immunosuppressive action, is widely used in treatment anaphylaxis and autoimmune inflammation disease.As connective tissue disease, activeness rheumatism, rheumatoid arthritis, lupus erythematosus, serious bronchial asthma, serious dermatitis, ulcerative colitis, acute leukemia etc., also be used for some severe infections and Comprehensive Treatment poisoning, malignant lymphoma.
scytitis such as eczema (eczema), allergic dermatitis (allergic dermatitis), atopic dermatitis (atopic dermatitis) urticaria (Urticaria) etc. is all to be caused allergy and caused scytitis by certain allergen, the allergic effect that causes skin allergic reaction is original multiple, wherein viral, fungus, the infection such as antibacterial cause one of major reason of scytitis, (detection and the clinical meaning thereof of allergy dermatitis patients serum fungus specific IgE such as Yuan Wei, Zunyi Medical College's journal, in February, 2004, 24-25) disclose in 136 routine allergic dermatitis patients and have 96 examples to be diagnosed as the merging fungal infection, the document thinks that fungal infection is important sensitizing agent in the various skin inflammation such as allergic dermatitis.Glucocorticoid is widely used in the treatment scytitis, but due to the immunosuppressive action of glucocorticoid, makes glucocorticoid not only can not reach the effect of antiinflammatory when being used for the treatment of the inflammation that the skin surface fungal infection causes, and can make on the contrary the inflammation aggravation.Affected the application of glucocorticoid when the treatment scytitis.Moreover because allergic dermatitis and noninfective allergic dermatitis that the infection such as fungus cause are quite similar on surface symptoms, be difficult to differentiate as not adopting microscopic examination, therefore easily cause clinically mistaken diagnosis, thereby delay treatment.And the dermatosis that causes for infection such as dermatophytess, although do not use glucocorticoid in treatment, but the sensitization due to microorganisms such as funguses, often be attended by the generation of allergic skin inflammation, (the impact of corticosteroid on fungus such as Jia Dongmei, foreign medical science skin cypridology fascicle, the 29th the 4th phase of volume in 2003,201-203) disclose in the cutaneous fungal infection experiment, after adopting antifungal drug treatment to infection to eliminate, animal often also has the inflammatory crust to exist, and illustrates that scytitis often more is difficult to treatment than infection itself.
NO is a kind of biological function inorganic molecules widely, participate in the metabolism of circulation, the system such as neural, immune and bone, synthetic by NOS (nitricoxide synthase) in vivo, the NO Developmental and Metabolic Disorder can cause the diseases such as rheumatic arthritis, asthma, apoplexy, presenile dementia, nitricoxide synthase (NOS) inhibitor is that a class can suppress nitric oxide synthase activity, thereby reduces the material of NO content in body.Studies have shown that multinomial thereby no inhibitor can be used for the treatment of the diseases associated with inflammation such as above-mentioned disease such as arthritis by the NO content that suppresses in NOS activity decreased body.But reducing the synthetic of NO, it may produce the main mechanism of the side reactions such as endothelial dysfunction, pain sensation sensitization, the better easing pain and diminishing inflammation effect (CN200880004081.5) that offshore company's NSAID (non-steroidal anti-inflammatory drug) is combined with nitric oxide of reporting is also arranged simultaneously, so nitric oxide, nitric oxide synthase inhibitors both which kind of can play in vivo better antiinflammation and also have larger difference, because pharmacological action is indistinct, side reaction is larger, so no inhibitor is not now also as medicament administration.The main amino acid derivativges of existing no inhibitor for research experiment such as L-N
6-(acetimidoyl)-lysine, NG-nitro-L-arginine, L-NMME, N ω, N ω-Asymmetric Dimethylarginine and S-methyl isothiourea, aminoguanidine etc.But we find S-methyl isothiourea and aminoguanidine etc. medicine, due to itself chemical property, when being used for the outer used time, exist larger zest when treatment, cause compliance not good.
Summary of the invention:
In constantly scientific research, the discovery that we are surprised, amino acid derivativges and methylprednisolone aceponate as no inhibitor are united use as skin-use preparation, compare with alone methylprednisolone aceponate, can significantly improve the therapeutic effect of methylprednisolone aceponate, and we find unexpectedly, and the coupling of these two kinds of medicines can also suppress local immunity power that the application due to methylprednisolone aceponate causes and reduce and cause side effect such as increasing the weight of infection.We also find when adopting Percutaneous absorption enhancer in addition, especially the uniting when using of ethylhexyl salicylate that accounts for the Isosorbide dimethyl ether of pharmaceutical composition percentage by weight 0.1-1% and account for pharmaceutical composition percentage by weight 1-5%, the pharmaceutical composition that obtains is suppressing the methylprednisolone aceponate side effect, and has produced beyond thought raising on the raising therapeutic effect.
The invention provides a kind of dermatologic compositions, contain as the methylprednisolone aceponate of active component with as the amino acid derivativges of no inhibitor, and one or more are applicable to excipient substance that skin uses and the water of surplus.
Described dermatologic compositions is characterized in that.Described amino acid derivativges as no inhibitor is L-N
6-(acetimidoyl)-lysine, NG-nitro-L-arginine, L-NMME, N ω, one or more of N ω-Asymmetric Dimethylarginine and ester thereof or salt.
Described dermatologic compositions, the weight proportion that it is characterized in that methylprednisolone aceponate and no inhibitor is 1: 0.1-10.Be preferably 1: 0.5-5, more preferably 1: 0.5-2.Described dermatologic compositions, described active component content is counted 0.01-0.2% with methylprednisolone aceponate, is preferably 0.05-0.1%.
Dermatologic compositions provided by the invention can be mixed with unguentum, gel, solution, spray, suspensoid etc., and all are applicable to the preparation that skin is used.The adjuvant that skin uses of being applicable to of described dermatologic compositions includes but are not limited to one or more in pH adjusting agent, antibiotic antiseptic, antioxidant, cosolvent, osmotic pressure regulator, viscosity modifier, surfactant, rheology control agent, oil-phase component, wetting agent, stabilizing agent.
PH adjusting agent in described adjuvant can be enumerated but be not limited only to one or more in phosphoric acid and salt, boric acid and salt thereof, citric acid and salt thereof, acetic acid and salt thereof, tartaric acid and salt thereof, hydrochloric acid, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, tromethane etc., one or more in preferred hydrochloric acid, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate.
Described osmotic pressure regulator can be enumerated but be not limited only to one or more in glycerol, propylene glycol, sodium chloride, potassium chloride, Sorbitol, mannitol, preferred sodium chloride.
Described viscosity modifier can be enumerated but be not limited only to one or more in sodium carboxymethyl cellulose, hydroxyethyl-cellulose, hydroxypropyl emthylcellulose, hydroxypropyl cellulose, polyvinyl alcohol, carboxy vinyl polymer, polyvinyl pyrrolidone.
Described wetting agent is selected from one or more in glycerol, propylene glycol, sorbitol, preferred glycerol.
Described antibiotic antiseptic is selected from benzoic acid, benzyl alcohol, p-Hydroxybenzoate (nipalgin), comprises one or more in methyl hydroxybenzoate, ethyl hydroxybenzoate, propylparaben, particularly preferably p-Hydroxybenzoate (nipalgin).
The optional non-ionic surface active agent of described surfactant, can enumerate but be not limited only to tween 80, HCO60, Polyethylene Glycol-stearate, Macrogol 4000, lecithin, sucrose ester, polyoxyethylene alkyl ether, one or more in polyoxyethylene polyoxypropylene glycol and analog thereof, poloxamer, tyloxapol.
When dermatologic compositions of the present invention is made gel, described adjuvant contains water and is the carbomer resin as rheology control agent, be particularly preferably carbomer 934 and/or Acritamer 940 and/or Carbopol 941, consumption is 0.1%～1% of pharmaceutical composition weight, preferred 0.2% to 0.5%.
When dermal drug compositions of the present invention is made ointment, describedly be applicable to the excipient substance that skin uses and contain wetting agent 1%～15%, oil-phase component 20%～30%, described wetting agent includes but are not limited to glycerol, propylene glycol, sorbitol, preferred glycerol, described oil-phase component comprise one or more in solid in oil-phase component, consistency modifiers, emulsifying agent.
Solid in described oil-phase component includes but are not limited to one or more of stearic acid, paraffin, Cera Flava, higher alcohol, described higher alcohol is the monohydric alcohol of 16～22 carbon atoms, preferred hexadecanol and/or octadecanol, described oil-phase component solid consumption is 1%～15%.
Described consistency modifiers includes but are not limited to one or more in vaseline, liquid paraffin, vegetable oil, preferred vaseline and/or liquid Paraffin, and the consumption of described consistency modifiers is 5%～20%.
Described emulsifying agent, preferred glyceryl monostearate and/or peregal A-20, preferred glyceryl monostearate consumption is 0.5%～10%, peregal A-20 consumption is 0.5%～8%.
Described higher alcohol also plays the effect of surfactant simultaneously in emulsifiable paste.Percentage ratio of the present invention is the percentage by weight of relative pharmaceutical composition.
Above degree is the percentage by weight of described dermatologic compositions.
The pH of dermatologic compositions provided by the invention is selected from 4-7
during described active component can adopt with the dispersion in compositions at described dermatologic and active fraction preparation be become micropowder and be scattered in compositions, or with active dissolution in organic solvent and be scattered in method in compositions, also can be prepared into cyclodextrin clathrate and be scattered in known methods such as method in compositions, preferred active fraction preparation becomes micropowder and is scattered in compositions, the method of micronization that adopts can adopt spray drying method, fluid bed supersonic jet mill method, the speed lapping method, ball-milling method, the fluid energy mill method, solvent method etc., the preferred spray drying method that adopts.
The micropowder that described methylprednisolone aceponate preferably is prepared into, the particle diameter of described micropowder are 0.5～50 μ m, preferred 5-30 μ m.
Described no inhibitor is preferably soluble in water when preparation.
Described dermatologic compositions, preferred,
also add Percutaneous absorption enhancer, described Percutaneous absorption enhancer is menthol, Borneolum Syntheticum, the quintessence oil class, isopropyl myristate, oleic acid, oleyl alcohol, cyclopentadecanone, dehydration sorbic acid sugar alcohol monoleate, the glycerol monoleate, PGML, polyethylene glycol monolaurate, 2-n-nonyl-1, the 3-dioxolanes, 2-(N, the N-dimethylamino)-propanoic acid-dodecyl ester or its salt derivative, 2 ethyl hexanoic acid-2-ethyl hexyl ester, Isosorbide dimethyl ether (CAS:5306-85-4), 4-decyl oxazolidine-2 ketone, 3-methyl-4-decyl oxazolidine-2 ketone, dimethyl-para-amino benzoic acid monooctyl ester, OctMet, ethylhexyl salicylate, laurocapram.Being preferably the use of uniting for the Isosorbide dimethyl ether that accounts for pharmaceutical composition percentage by weight 0.1-1% and the ethylhexyl salicylate that accounts for pharmaceutical composition percentage by weight 1-5%, is more preferably the use of uniting that accounts for Isosorbide dimethyl ether with the ethylhexyl salicylate that accounts for pharmaceutical composition percentage by weight 3% of pharmaceutical composition percentage by weight 0.1-0.3%.
Particle diameter of the present invention is mass median diameter (mass mean diameter).
Dermatologic compositions provided by the invention, can be used in dermatosis particularly scytitis treatment, the scytitis that particularly infects for concurrent antibacterial, can suppress local immunity power that the side effect because of methylprednisolone aceponate causes reduces the infection that causes and increases the weight of, can alleviate significantly the symptom of laboratory animal, produce beyond thought therapeutic effect.When special in addition when the methylprednisolone aceponate in active component is prepared into micropowder, nos inhibitor selects when soluble in water, add Percutaneous absorption enhancer, can better promote absorption and effect that NOS suppresses, but can not increase the systemic Absorption of methylprednisolone aceponate, thereby can better bring into play the effect that no inhibitor suppresses the methylprednisolone aceponate side effect, produce better therapeutic effect, be specially adapted to existing the treatment as the scytitis of fungal infection.Particularly the present invention preferably unites the cutaneous permeable agent of use, compares with alone any one cutaneous permeable agent, has produced beyond thought effect, has better brought into play the therapeutic effect of 17-hydroxy-11-dehydrocorticosterone and has suppressed its side effect.
The specific embodiment
Prepared various pharmaceutical composition all need be sterilized.Methylprednisolone aceponate all need be ground into the micropowder of 5 μ m to 30 μ m with mechanical activation comminution or other forms before preparation, the skin composition that provides in the embodiment of the present invention is all in 1000ml.Process for preparation preferably carries out under nitrogen protection.The pharmaceutical composition that embodiment prepares can be distributed into solution, also can divide to install to and make spray in aerosol container.
Embodiment 1
L-N6-(acetimidoyl)-lysine 5g, sodium chloride is appropriate, sodium carboxymethyl cellulose 2.5g, poloxamer 0.5g, methylprednisolone aceponate 0.5g, the water for injection of surplus
Compound method: sodium carboxymethyl cellulose, the poloxamer of recipe quantity are dissolved in 500ml water for injection, stir molten clearly, add the L-N6-(acetimidoyl) of recipe quantity-lysine, transfer pH to 5.5.The methylprednisolone aceponate micropowder that adds recipe quantity adds the water for injection of surplus.Transfer to etc. with sodium chloride and ooze, packing.Resulting composition no inhibitor %=0.5%, methylprednisolone aceponate %=0.05%.
Embodiment 2 gels
L-NMME 10g, glycerol 50ml, carbomer 934 2g, methylprednisolone aceponate 1g,
The carbomer 934 of getting recipe quantity adds the glycerol moistening to grind, adding 500ml purified water swelling as gel-type vehicle, the methylprednisolone aceponate micropowder of recipe quantity is joined in gel-type vehicle stir evenly, again with the L-NMME of recipe quantity, be dissolved in suitable quantity of water, slowly join in gel-type vehicle and stir evenly, sodium hydroxide adjust pH to 5.5 with appropriate 1mol/L adds the water of surplus and get final product.Resulting composition no inhibitor %=1%, methylprednisolone aceponate=0.1%.
Embodiment 2-1
Fill a prescription identical with embodiment 2, separately get menthol 10g, be dissolved in the recipe quantity glycerol, other compound methods are identical with embodiment 2.
Embodiment 3 ointments
N ω, N ω-Asymmetric Dimethylarginine 1g, glycerol 50g
Methylprednisolone aceponate, 0.2g
The formula of oil phase:
White vaseline 60g octadecanol 30g liquid Paraffin 30g glyceryl monostearate 50g peregal a-2010g
Preparation:
1. the preparation of oil phase
The oil-phase component of getting recipe quantity is heated to 70 ℃, then the glycerol of getting recipe quantity is heated to same temperature and slowly joins in oil phase, stirs while adding to evenly and get final product.
The preparation of emulsifiable paste
With N ω, N ω-Asymmetric Dimethylarginine is dissolved in suitable quantity of water, adds the methylprednisolone aceponate micropowder that is scattered in water, supplementing water is heated to 65 ℃ to recipe quantity, the oil-phase component that will be heated to again 70 ℃ adds, and stirs while adding evenly to condensation and get final product.Resulting composition no inhibitor %=0.1%, methylprednisolone aceponate %=0.02%.
Embodiment 3-1
Fill a prescription identical with embodiment 3, separately get OctMet 10g, be dissolved in the recipe quantity glycerol, compound method is identical with embodiment 3.
Embodiment 3-2 ointment
Will be except methylprednisolone aceponate change 0.1g into, other formulas, preparation method are identical with embodiment 3-1, make compositions, resulting composition no inhibitor %=0.1%, methylprednisolone aceponate %=0.01%.
Embodiment 4
NG-nitro-L-arginine 0.2g, sodium chloride is appropriate, hydroxypropyl cellulose 2.5g, tyloxapol 1.0g methylprednisolone aceponate 2g, the water for injection of surplus
Compound method: hydroxypropyl cellulose, the tyloxapol of recipe quantity are dissolved in 500ml water for injection, stir molten clearly, add the NG-nitro-L-arginine of recipe quantity, transfer pH to 5.0.Add after recipe quantity methylprednisolone aceponate micropowder is disperseed with water-wet, then add the water for injection of surplus.Transfer to etc. with sodium chloride and ooze, packing.Resulting composition no inhibitor %=0.02%, methylprednisolone aceponate %=0.2%
Embodiment 4-1
Fill a prescription identical with embodiment 4, separately get laurocapram 10g, be dissolved in the recipe quantity glycerol, other compound methods are identical with embodiment 4.
Embodiment 5
L-NMME 0.4g, glycerol 50ml, carbomer 934 5g methylprednisolone aceponate 2g
The carbomer 934 of getting recipe quantity adds the glycerol moistening to grind, adding 500ml purified water swelling as gel-type vehicle, slowly join in gel-type vehicle after the methylprednisolone aceponate micropowder of recipe quantity is disperseed with water-wet and stir evenly, L-NMME with recipe quantity is dissolved in suitable quantity of water again, slowly join in gel-type vehicle and stir evenly, sodium hydroxide with appropriate 1mol/L is transferred pH to 5.5, adds excess water and get final product.Resulting composition no inhibitor %=0.04%, methylprednisolone aceponate %=0.2%.
Embodiment 5-1
Fill a prescription identical with embodiment 5, separately get isopropyl myristate 10g, be dissolved in the recipe quantity glycerol, compound method is identical with embodiment 5.
Embodiment 6
N ω, N ω-Asymmetric Dimethylarginine 2g
Methylprednisolone aceponate 2g, glycerol 120g
The formula of oil phase:
White vaseline 30g octadecanol 120g liquid Paraffin 10g glyceryl monostearate 20g peregal a-2050g
Preparation:
2. the preparation of oil phase
The oil-phase component of getting recipe quantity is heated to 70 ℃, then the glycerol of getting recipe quantity is heated to same temperature and slowly joins in oil phase, stirs while adding to evenly and get final product.
The preparation of emulsifiable paste
With N ω, N ω-Asymmetric Dimethylarginine is dissolved in suitable quantity of water, adds the methylprednisolone aceponate micropowder that is scattered in water, supplementing water is to recipe quantity, be heated to again 65 ℃, then will be heated to the oil-phase component of 70 ℃ and add, stir while adding evenly to condensation and get final product.Resulting composition no inhibitor %=0.2%, methylprednisolone aceponate %=0.2%.
Embodiment 6-1
Fill a prescription identical with embodiment 6, separately get ethylhexyl salicylate 30g, be dissolved in the recipe quantity glycerol, compound method is identical with embodiment 6.
Embodiment 7
L-N6-(acetimidoyl)-lysine 1g, sodium chloride is appropriate, hydroxypropyl emthylcellulose 5g, the appropriate methylprednisolone aceponate 0.5g of tyloxapol 2g sodium hydroxide, the water for injection of surplus
Compound method: hydroxypropyl emthylcellulose, the tyloxapol of recipe quantity are dissolved in 500ml water for injection, stir molten clearly, add the L-N6-(acetimidoyl) of recipe quantity-lysine, transfer pH to 5.5 with sodium hydroxide.Add after recipe quantity methylprednisolone aceponate micropowder is disperseed with water-wet, add the water for injection of surplus.Transfer to etc. with sodium chloride and ooze, packing.Resulting composition no inhibitor %=0.1%, methylprednisolone aceponate %=0.05%.
Embodiment 8
NG-nitro-L-arginine 1g, glycerol 150g
Methylprednisolone aceponate 0.5g
The formula of oil phase:
White vaseline 90g octadecanol 60g liquid Paraffin 60g glyceryl monostearate 10g peregal a-2030g
Preparation:
1. the preparation of oil phase
The oil-phase component of getting recipe quantity is heated to 70 ℃, then the glycerol of getting recipe quantity is heated to same temperature and slowly joins in oil phase, stirs while adding to evenly and get final product.
2. the preparation of emulsifiable paste
NG-nitro-L-arginine is dissolved in suitable quantity of water, adds the methylprednisolone aceponate micropowder that is scattered in water, supplementing water is to recipe quantity, then is heated to 65 ℃, then will be heated to the oil-phase component of 70 ℃ and add, and stirs while adding evenly to condensation and get final product.Resulting composition no inhibitor %=0.1%, methylprednisolone aceponate %=0.05%.
Embodiment 8-1
Fill a prescription identical with embodiment 8, separately get ethylhexyl salicylate 30g, be dissolved in the recipe quantity glycerol, other compound methods are identical with embodiment 8.
Embodiment 8-2
Fill a prescription identical with embodiment 8, separately get ethylhexyl salicylate 30g and 1g Isosorbide dimethyl ether, be dissolved in the recipe quantity glycerol, other compound methods are identical with embodiment 8.
Embodiment 8-3
Fill a prescription identical with embodiment 8, separately get and separately get ethylhexyl salicylate 30g and 3g Isosorbide dimethyl ether, be dissolved in the recipe quantity glycerol, other compound methods are identical with embodiment 8.
Embodiment 9
L-NMME 2g, sodium chloride is appropriate, hydroxypropyl emthylcellulose 2g, tyloxapol 2g, methylprednisolone aceponate 1g, the water for injection of surplus
Compound method: with recipe quantity, hydroxypropyl emthylcellulose, tyloxapol be dissolved in 500ml water for injection, stirs molten clearly, adds the L-NMME dissolving of recipe quantity, transfers pH to 6.0.Add the methylprednisolone aceponate micropowder that is scattered in water, add the water for injection of surplus.Transfer to etc. with sodium chloride and ooze, packing.Resulting composition no inhibitor %=0.2%, methylprednisolone aceponate %=0.1%.
Embodiment 10
N ω, N ω-Asymmetric Dimethylarginine 1g
Sodium chloride is appropriate, carboxymethyl cellulose 2g, poloxamer 2g
Methylprednisolone aceponate 1g,
The water for injection of surplus
Compound method: carboxymethyl cellulose, the poloxamer of recipe quantity are dissolved in 500ml water for injection, stir molten clearly, add the N ω of recipe quantity, N ω-Asymmetric Dimethylarginine is transferred pH to 6.0.Add the methylprednisolone aceponate that is scattered in water, add the water for injection of surplus.Transfer to etc. with sodium chloride and ooze, packing.Resulting composition no inhibitor %=0.1%, methylprednisolone aceponate %=0.1%
Embodiment 11
L-NMME 0.2g sodium chloride is appropriate, polyvinylpyrrolidone 1g, and poloxamer 2g, methylprednisolone aceponate 0.2g,
The water for injection of surplus
Compound method: polyvinylpyrrolidone, the poloxamer of recipe quantity are dissolved in 500ml water for injection, stir molten clearly, add the L-NMME of recipe quantity, transfer pH to 6.0 with sodium hydroxide.The methylprednisolone aceponate that adds recipe quantity adds the water for injection of surplus.Transfer to etc. with sodium chloride and ooze, packing.Resulting composition no inhibitor %=0.02%, methylprednisolone aceponate %=0.02%
Pharmacology embodiment
Laboratory animal: albino guinea-pig, one-level, male and female half and half, body weight 200-250g plant in Britain
Fungal infection: alpha fungus (bacterium T
5cT.men-tagrophyte, trichophyton), provided by China Committee for Culture Collection of Microorganisms's medical mycology center, recover its pathogenicity before experiment and be inoculated in husky fort agar (Sabrouraud dextrose agar SDA) slant tube, 26 ℃ of cultivations, careful scraping bacterium colony after 10d is made with normal saline and is contained spore count 105/ml suspension
Get Cavia porcellus, electricity consumption pushes away one side depilation 3cm * 8cm area at its back, after 24h, with the central skin of the broken depilation face of aseptic fine sandpaper sassafras, take slight oozing of blood as degree, causing area is 2cm * 6cm rectangle wound face, evenly inoculate again the above-mentioned bacterial strains suspension on wound face, every 1cm2 inoculation 1ml.Room temperature keeps 30 ℃, after 10d the animal inoculation fungus go out skin occur erythra, squama or or crust, scraping erythra, squama or crust microscopy can be seen alpha fungus mycelia and spore., representing lesion degree with " 0,1,2,3,4 " classification, criterion is: expression in 0 minute is without skin lesion, and 1 is divided into the point-like erythema, and 2 are divided into the gamut erythema, and 3 are divided into redness, squama, and 4 are divided into erythema, the incrustation that overruns.Getting scoring is Cavia porcellus more than 3 minutes, random packet, and every group of 10 administration and grouping see the following form:
Experimental technique, each experimental group is administered once every day, evenly smears Experimental agents once in the laboratory animal affected part at every turn, and it is identical that each organizes each administration emulsifiable paste amount, and 3d, 7d after administration mark to the laboratory animal affected part respectively
Show by pharmacological evaluation, compare with the matched group 13 as negative control, so significant therapeutic effect that the laboratory animal of experimental group all produces, and use merely the matched group 1-11 of methylprednisolone aceponate external curing, and added Percutaneous absorption enhancer, but also use merely the matched group of methylprednisolone aceponate relatively poor, especially obviously do not improve through the treatment symptom of 7 days, what have deterioration even occurred.Pharmaceutical composition provided by the invention is described, by adding no inhibitor, has suppressed methylprednisolone aceponate in antiinflammatory, thereby reduce the side effect that skin surface immunity causes that infection increases the weight of.Particularly in each experimental group, used experimental group 2-1,3-1,4-1,5-1,6-1, the 8-1 of the pharmaceutical composition with Percutaneous absorption enhancer to compare with experimental group 2-6,8 respectively, therapeutic effect has also produced obvious raising, especially 8-2,8-3 group curative effect is compared with experimental group 2-1,3-1,4-1,5-1,6-1,8-1, the raising of therapeutic effect is more obvious, illustrates in Percutaneous absorption enhancer as according to ratio provided by the invention, ethylhexyl salicylate and isopropyl myristate coupling successful are better than other cutaneous permeable agents to use separately.And add each experimental group of cutaneous permeable agent, therapeutic effect is also significantly better than the experimental group that does not use cutaneous permeable agent of same dosage, the effect that can improve no inhibitor that adds of Percutaneous absorption enhancer is described, better suppress the side effect of methylprednisolone aceponate, improve the therapeutic effect of medicine.
Pharmacology embodiment 3, transdermal permeation in vitro
After getting the healthy rat anesthesia execution of 3 monthly ages, eliminate belly wool with shears, take off undamaged skin, remove subcutaneous tissue, be individually fixed in the liberation port of Franz diffusion cell after cleaning, add the pH7.4 phosphate buffer to make release medium in receiving chamber, keep endodermis and solution close contact.Get the 0.1ml medicinal liquid and be coated on skin, regulate water-bath and make outer jacket layer temperature constant in (37 ± 1) degree, mixing speed is 100rpm, respectively at 0,0.15,0.5,0.75,1,1.5,2 hour absorption release medium 4ml, adds simultaneously equivalent PBS liquid.Discharge liquid and determine concentration C i with the method for Chinese Pharmacopoeia version in 2010, try to achieve drug per unit area accumulation transit dose Q:Q=CiV/A according to following formula.In formula, Q is drug per unit area accumulation transit dose, and Ci is the drug level in release medium in the t time, and V is the receiving chamber volume, and A is the skin diffusion area.With Q and C, the time is carried out linear regression respectively, try to achieve permeability (J/ μ g.h
-1)
The preparation of Experimental agents: take the fluticasone propionate of same dose, momestasone furoate, hydrocortisone butyrate as replacing methylprednisolone aceponate as the glucocorticoid in active component, nos inhibitor and other adjuvants are according to the formula of embodiment 8-2 or 8-3, preparation becomes Comparative Examples 1-6, formula and active component such as following table
Get embodiment 8 and 8-1～8-3, and the pharmaceutical composition that gets of reference examples 1-6 class value, carry out the body outer osmotic test, Experimental agents sugar cortex micropowder mean diameter all between 15-18 μ m, can think in this experiment particle diameter on permeability without impact.Result is as follows:
| Numbering | Glucocorticoid J (μ g.h -1) | Numbering | Glucocorticoid J (μ g.h -1) |
| Embodiment 8 | 4.01 | Comparative Examples 2 | 16.56 |
| Embodiment 8-1 | 16.13 | Comparative Examples 3 | 15.26 |
| Embodiment 8-2 | 19.26 | Comparative Examples 4 | 16.41 |
| Embodiment 8-3 | 20.71 | Comparative Examples 5 | 15.61 |
| Comparative Examples 1 | 15.98 | Comparative Examples 6 | 16.21 |
Test shows, as the embodiment 8-1～8-3 that adopts Percutaneous absorption enhancer, its drug osmotic rate is apparently higher than the embodiment 8 that is not used in Percutaneous absorption enhancer.But used particularly preferred embodiment 8-2, the 8-3 that unites the cutaneous permeable agent of use of the present invention, the permeability of methylprednisolone aceponate is apparently higher than embodiment 8-1, and the permeability of no inhibitor does not have significant change, and we find unexpectedly simultaneously, same dose and formula, but adopt the reference examples 1-6 of the glucocorticoid of other kinds, the permeability of its glucocorticoid and embodiment 8-1 are substantially suitable, thereby illustrate that preferably uniting the permeability of using Percutaneous absorption enhancer can specifically increase methylprednisolone aceponate improves its therapeutic effect.
Claims (10)
1. dermatologic compositions, contain as the methylprednisolone aceponate of active component with as the NG-nitro-L-arginine of no inhibitor, as the Isosorbide dimethyl ether that accounts for pharmaceutical composition percentage by weight 0.1-1% of Percutaneous absorption enhancer with account for the ethylhexyl salicylate of pharmaceutical composition percentage by weight 1-5%, and one or more are applicable to excipient substance that skin uses and the water of surplus.
2. dermatologic compositions as claimed in claim 1, the mass ratio that it is characterized in that described methylprednisolone aceponate and no inhibitor is 1: 0.1-10.
3. dermatologic compositions as claimed in claim 1 is characterized in that described active component content counts 0.01-0.2% with methylprednisolone aceponate.
4. dermatologic compositions as described in as arbitrary in claim 1-4 is characterized in that being mixed with unguentum, gel, solution, spray, suspensoid.
5. dermatologic compositions as claimed in claim 4 is characterized in that describedly being applicable to adjuvant that skin uses and including but are not limited to one or more in pH adjusting agent, antibiotic antiseptic, antioxidant, cosolvent, osmotic pressure regulator, viscosity modifier, surfactant, rheology control agent, oil-phase component, wetting agent, stabilizing agent.
6. dermatologic compositions as claimed in claim 4, is characterized in that pH is selected from 4-7.
7. dermatologic compositions as claimed in claim 4, when it is characterized in that described dermatologic compositions is made gel, described adjuvant contains water and is the carbomer resin as rheology control agent.
8. dermatologic compositions as claimed in claim 4 when it is characterized in that described dermatologic compositions is made ointment, describedly is applicable to the excipient substance that skin uses and contains wetting agent 1%～15%, oil-phase component 20%～30%.
9. dermatologic compositions as claimed in claim 4 is characterized in that described viscosity modifier can enumerate but be not limited only to one or more in sodium carboxymethyl cellulose, hydroxyethyl-cellulose, hydroxypropyl emthylcellulose, hydroxypropyl cellulose, polyvinyl alcohol, carboxy vinyl polymer, polyvinyl pyrrolidone.
10. dermatologic compositions as claimed in claim 1, is characterized in that the micropowder that described methylprednisolone aceponate preferably is prepared into, and the particle diameter of described micropowder is 0.5～50 μ m.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103919264A CN103127136A (en) | 2011-11-30 | 2011-11-30 | Skin drug composition containing methylprednisolone aceponate and amino acid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103919264A CN103127136A (en) | 2011-11-30 | 2011-11-30 | Skin drug composition containing methylprednisolone aceponate and amino acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103127136A true CN103127136A (en) | 2013-06-05 |
Family
ID=48488008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103919264A Pending CN103127136A (en) | 2011-11-30 | 2011-11-30 | Skin drug composition containing methylprednisolone aceponate and amino acid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103127136A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107519181A (en) * | 2016-06-20 | 2017-12-29 | 天津金耀集团有限公司 | Dermopharmaceutical composition using Methylprednisolone Aceponate as active component |
| US20190216823A1 (en) * | 2018-01-12 | 2019-07-18 | Hyloris Developments Sa | Methylprednisolone pharmaceutical suspension |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102078326A (en) * | 2009-11-26 | 2011-06-01 | 天津金耀集团有限公司 | Topically applied composition containing povidone iodine and mometasone furoate |
-
2011
- 2011-11-30 CN CN2011103919264A patent/CN103127136A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102078326A (en) * | 2009-11-26 | 2011-06-01 | 天津金耀集团有限公司 | Topically applied composition containing povidone iodine and mometasone furoate |
Non-Patent Citations (2)
| Title |
|---|
| 方玉蓉等: "布地奈德联合不对称二甲基精氨酸对哮喘大鼠气道炎症和PCⅢ表达的影响", 《中国药师》 * |
| 方玉蓉等: "布地奈德联合不对称二甲基精氨酸对哮喘大鼠气道炎症和PCⅢ表达的影响", 《中国药师》, no. 09, 31 December 2005 (2005-12-31) * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107519181A (en) * | 2016-06-20 | 2017-12-29 | 天津金耀集团有限公司 | Dermopharmaceutical composition using Methylprednisolone Aceponate as active component |
| US20190216823A1 (en) * | 2018-01-12 | 2019-07-18 | Hyloris Developments Sa | Methylprednisolone pharmaceutical suspension |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210236562A1 (en) | Compositions for the treatment of skin conditions | |
| US10973841B2 (en) | Compositions for the treatment of skin conditions | |
| EP2266626B1 (en) | Composition for external application comprising transcription factor decoy as active ingredient | |
| RU2536264C2 (en) | Topical dermal composition containing salt and sugar as active ingredients for preventing and treating vaginosis, and using it | |
| JP2019513769A (en) | Use of Gram-negative species to treat atopic dermatitis | |
| CN103099778B (en) | The externally-applied medicinal composition of a kind of fluocinolone acetonide and ester thereof | |
| CN103705922B (en) | Using glucocorticoid as the externally-applied medicinal composition of active constituent | |
| CN102078326A (en) | Topically applied composition containing povidone iodine and mometasone furoate | |
| BR112021001206A2 (en) | use of gram negative species to treat atopic dermatitis | |
| CN102949723A (en) | Medicinal composition containing glucocorticoid and NOS (Nitric Oxide Synthase) inhibitor for treating skin inflammation | |
| CN103127136A (en) | Skin drug composition containing methylprednisolone aceponate and amino acid | |
| CN102078611A (en) | Partial external use composition containing povidone Iodine and cyclodextrin inclusion glucocorticoid | |
| CN103127132A (en) | Dermal medicine composition containing fluticasone propionate and nitric oxide synthase (NOS) inhibitor | |
| CN103127137A (en) | Medicine combination with hydrocortisone butyrate and nitric oxide synthase (NOS) inhibitor and for treating skin inflammation | |
| CN103127142A (en) | Dermal medicine composition containing mometasone furoate and amino acid derivative | |
| CN103655460B (en) | Injection medicinal composition containing aztreonam, as well as preparation method and application thereof | |
| CN117338717B (en) | A baicalein external preparation and its application in treating atopic dermatitis | |
| CN104367636A (en) | Oil-in-water type compound ceftriaxone nanoemulsion antimicrobial medicine | |
| CN102552287A (en) | Skin percutaneous absorption drug of adjuvant-containing mometasone furoate and adjuvant-containing water | |
| CN104784102A (en) | Ceftezole sodium ointment | |
| CN102525913A (en) | Separated water suspension medicine composed of hydrocortisone butyrate and water containing accessories and used for treating dermatosis | |
| CN103705441A (en) | Beclomethasone dipropionate emulsifiable paste | |
| CN102552283A (en) | Transdermal absorption drug for skin prepared from hydrocortisone butyrate containing adjuvant and water containing adjuvant | |
| CN102552282A (en) | Transdermal absorption medicament used for skins and comprising adjuvant-containing methylprednisolone aceponate and adjuvant-containing water | |
| CN102475888A (en) | Transdermal drug containing adjuvant-containing drug particles and adjuvant-containing water for skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130605 |